Endoscopic Treatment of Benign Biliary Strictures and Cystic Duct Leakages With a Novel Biodegradable Biliary Stent
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02353286 |
Recruitment Status :
Completed
First Posted : February 2, 2015
Last Update Posted : May 14, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Biliary Tract Diseases | Device: Endoscopic insertion of biodegradable biliary stent | Not Applicable |
Benign biliary strictures (BBS) and post-cholecystectomy bile leaks have traditionally been treated endoscopically with plastic stents. In BBS, promising results of covered self-expanding metal stent use have been recently published. However, in both BBS and post-cholecystectomy bile leak the need of stent therapy is temporary and endoscopic stent exchange or removal is unavoidable. These two groups of patients may be the ones that would most obviously benefit from biodegradable (BD) biliary stents. Studies of BD stents on animal models have shown excellent long term patency and safety both in biliary and pancreatic duct as well better outcome compared to plastic stents after post-cholecystectomy bile leak in an animal study. Until recently, non-operative insertion of BD polydioxanone stent in human biliary tract has been possible only via percutaneous route.
With the novel implantation device, the BD stents (braided, self-expanding polydioxanone stent, 8 x 40-60mm, Ella, Czech republic) may be used endoscopically during endoscopic retrograde cholangio-pancreatography (ERCP).
The hypothesis is that larger diameter and radial expansion strength provide at least similar treatment success as the current method of endoscopic insertion of plastic or covered self-expanding metal stents in bile leak and BBS, respectively. However, later stent exchange or removal is not necessary with BD stents.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 14 participants |
Allocation: | Non-Randomized |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Endoscopic Treatment of Benign Biliary Strictures and Cystic Duct Leakages With a Novel Biodegradable Polydioxanone Biliary Stent |
Study Start Date : | May 2014 |
Actual Primary Completion Date : | December 31, 2017 |
Actual Study Completion Date : | December 31, 2017 |
Arm | Intervention/treatment |
---|---|
Experimental: Post-cholecystecomy bile leak
Endoscopic insertion of biodegradable biliary stent
|
Device: Endoscopic insertion of biodegradable biliary stent
Endoscopic insertion of biodegradable biliary stent
Other Name: Braided, self-expanding polydioxanone stent, Ella, Czech Rep |
Experimental: Benign biliary stricture
Endoscopic insertion of biodegradable biliary stent
|
Device: Endoscopic insertion of biodegradable biliary stent
Endoscopic insertion of biodegradable biliary stent
Other Name: Braided, self-expanding polydioxanone stent, Ella, Czech Rep |
- Clinical treatment success of stricture or leakage, treatment failure rate measured by change in treatment protocol or unplanned interventions, radiologic stricture diameter in MRI, radiologic stent degradation in MRI [ Time Frame: The follow-up of 12 months after stent implantation ]Stent patency, unplanned admissions and interventions, signs of cholangitis during treatment assessed by repeated liver function tests, magnetic resonance imaging and interview. Change in stent diameter and gradual radiologic dissappearance due to degradation assessed by repeated MRI and liver function tests, stricture resolution assessed by repeated MRI and radiologic measurement of stricture width as well as liver function tests, leakage resolution assessed by disappearance of biliary fluid collection in MRI and liver function tests
- ERCP complications, late adverse events during stent therapy [ Time Frame: 30 days from stent implantation, late adverse events up to 12 months ]endoscopic retrograde cholangio-pancreatography (ERCP) and stent implantation related complications graded mild-moderate-severe according to Cotton et al 1991, unplanned admissions and incidence of late adverse events such as acute cholangitis until up to 12 months of follow-up assessed by repeated MRI, phone interview, blood samples and review of patient records at each follow-up contact.
- Technical success of stent insertion [ Time Frame: intraoperative ]To assess the usefulness and safety of a novel endoscopic implantation device measured by success rate of stent implantation and evaluation possible intra-procedural technical challenges during ERCP

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- informed-consent patients with diagnosed or suspected post-cholecystectomy biliary leak or benign biliary stricture.
Exclusion Criteria:
- Patients with contra-indications for magnetic resonance imaging (MRI) or surgically altered gastro-duodenal anatomy (e.g. roux-y-loop) are excluded from the study.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02353286
Finland | |
Tampere University Hospital, Dept. of Gastroenterology and Alimentary Tract Surgery | |
Tampere, Finland, 33521 |
Study Director: | Johanna Laukkarinen, Md, PhD | Dept. of Gastroenterology and Alimentary Tract Surgery | |
Study Director: | Juhani Sand, Md, PhD | Dept. of Gastroenterology and Alimentary Tract Surgery |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Antti Siiki, MD, Tampere University Hospital |
ClinicalTrials.gov Identifier: | NCT02353286 |
Other Study ID Numbers: |
Biodegradable Biliary stent |
First Posted: | February 2, 2015 Key Record Dates |
Last Update Posted: | May 14, 2018 |
Last Verified: | May 2018 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Biodegradable stents, ERCP |
Biliary Tract Diseases Digestive System Diseases |